Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines

S. M. Moghimi; Thomas Lars Andresen

doi:10.1016/j.molimm.2009.02.014

Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines

S. M. Moghimi
, Thomas Lars Andresen

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

The recent unexpected observation that complement activation helps turnout growth and progression has an important bearing on the future development of cancer nanomedicines for site-specific tumour targeting as these entities are capable of triggering complement. These issues are discussed and suggestions are provided for future design and development of safer and effective cancer nanomedicines.

Original language	English
Journal	Molecular Immunology
Volume	46
Issue number	8-9
Pages (from-to)	1571-1572
ISSN	0161-5890
DOIs	https://doi.org/10.1016/j.molimm.2009.02.014
Publication status	Published - 2009

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Complement system
Nanoparticles
C5a
Cancer

Access to Document

10.1016/j.molimm.2009.02.014

OpenUrl availability

Check availability in DTU Findit

Cite this

@article{ee9d74d2fc294e3882363e31c3b80775,

title = "Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines",

abstract = "The recent unexpected observation that complement activation helps turnout growth and progression has an important bearing on the future development of cancer nanomedicines for site-specific tumour targeting as these entities are capable of triggering complement. These issues are discussed and suggestions are provided for future design and development of safer and effective cancer nanomedicines.",

keywords = "Complement system, Nanoparticles, C5a, Cancer",

author = "Moghimi, \{S. M.\} and Andresen, \{Thomas Lars\}",

year = "2009",

doi = "10.1016/j.molimm.2009.02.014",

language = "English",

volume = "46",

pages = "1571--1572",

journal = "Molecular Immunology",

issn = "0161-5890",

publisher = "Elsevier",

number = "8-9",

}

TY - JOUR

T1 - Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines

AU - Moghimi, S. M.

AU - Andresen, Thomas Lars

PY - 2009

Y1 - 2009

N2 - The recent unexpected observation that complement activation helps turnout growth and progression has an important bearing on the future development of cancer nanomedicines for site-specific tumour targeting as these entities are capable of triggering complement. These issues are discussed and suggestions are provided for future design and development of safer and effective cancer nanomedicines.

AB - The recent unexpected observation that complement activation helps turnout growth and progression has an important bearing on the future development of cancer nanomedicines for site-specific tumour targeting as these entities are capable of triggering complement. These issues are discussed and suggestions are provided for future design and development of safer and effective cancer nanomedicines.

KW - Complement system

KW - Nanoparticles

KW - C5a

KW - Cancer

U2 - 10.1016/j.molimm.2009.02.014

DO - 10.1016/j.molimm.2009.02.014

M3 - Journal article

C2 - 19286261

SN - 0161-5890

VL - 46

SP - 1571

EP - 1572

JO - Molecular Immunology

JF - Molecular Immunology

IS - 8-9

ER -

Complement-mediated tumour growth: implications for cancer nanotechnology and nanomedicines

Abstract

UN SDGs

Keywords

Access to Document

OpenUrl availability

Fingerprint

Cite this